- Home
- JKHY vs INCY Comparison
JKHY vs INCY Comparison
Compare JKHY & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JKHY
- INCY
- Stock Information
- Founded
- JKHY 1976
- INCY 1991
- Country
- JKHY United States
- INCY United States
- Employees
- JKHY N/A
- INCY N/A
- Industry
- JKHY Retail: Computer Software & Peripheral Equipment
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- JKHY Technology
- INCY Health Care
- Exchange
- JKHY Nasdaq
- INCY Nasdaq
- Market Cap
- JKHY 11.9B
- INCY 17.0B
- IPO Year
- JKHY N/A
- INCY 1993
- Fundamental
- Price
- JKHY $164.01
- INCY $104.52
- Analyst Decision
- JKHY Hold
- INCY Buy
- Analyst Count
- JKHY 9
- INCY 19
- Target Price
- JKHY $176.22
- INCY $89.19
- AVG Volume (30 Days)
- JKHY 971.5K
- INCY 2.8M
- Earning Date
- JKHY 11-04-2025
- INCY 10-28-2025
- Dividend Yield
- JKHY 1.42%
- INCY N/A
- EPS Growth
- JKHY 20.28
- INCY 3878.02
- EPS
- JKHY 6.58
- INCY 5.90
- Revenue
- JKHY $2,419,044,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- JKHY $6.98
- INCY $19.33
- Revenue Next Year
- JKHY $6.45
- INCY $10.47
- P/E Ratio
- JKHY $24.87
- INCY $17.60
- Revenue Growth
- JKHY 7.75
- INCY 18.09
- 52 Week Low
- JKHY $144.12
- INCY $53.56
- 52 Week High
- JKHY $196.00
- INCY $109.28
- Technical
- Relative Strength Index (RSI)
- JKHY 62.03
- INCY 68.82
- Support Level
- JKHY $159.78
- INCY $103.77
- Resistance Level
- JKHY $168.43
- INCY $109.28
- Average True Range (ATR)
- JKHY 3.33
- INCY 3.82
- MACD
- JKHY 0.77
- INCY -0.06
- Stochastic Oscillator
- JKHY 80.45
- INCY 75.05
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.